Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 6, 2013, Pages 718-728

  Tlili, Asma ^a   Jacobs, Frank ^b   de Koning, Leanne ^c   Mohamed, Sirine ^a   Bui, Linh Chi ^a   Dairou, Julien ^a   Belin, Nicole ^d   Ducros, Véronique ^d   Dubois, Thierry ^c   Paul, Jean Louis ^e,f   Delabar, Jean Maurice ^a   De Geest, Bart ^b   Janel, Nathalie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c INSTITUT CURIE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f EA 4529   (France)

Author keywords

Akt GSK3 pathway; Aorta; Apolipoprotein A I; Dyrk1a gene transfer; Homocysteine; Pyridoxal phosphate

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CYSTATHIONINE BETA SYNTHASE; DYRK1A PROTEIN; GLYCOGEN SYNTHASE KINASE 3; HOMOCYSTEINE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRIDOXAL 5 PHOSPHATE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE TRANSFER; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; CYSTATHIONINE BETA-SYNTHASE; GENETIC THERAPY; HEPATOCYTES; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MICE; MICE, MUTANT STRAINS; ORGAN SPECIFICITY; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TRANSDUCTION, GENETIC;

EID: 84875065604     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.02.008     Document Type: Article

References (54)

1. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998, 338:1042-1050.
2. Selhub J. Homocysteine metabolism. Annu. Rev. Nutr. 1999, 19:217-246.
3. Szegedi S.S., Castro C.C., Koutmos M., Garrow T.A. Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase. J. Biol. Chem. 2008, 283:8939-8945.
4. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., Andria G., Boers G.H.J., Bromberg I.L., Cerone R., Fowler B., Gröbe H., Schmidt H., Schweitzer L. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 1985, 37:1-31.
5. Yap S., Boers G.H., Wilcken B., Wilcken D.E., Brenton D.P., Lee P.J., Walter J.H., Howard P.M., Naughten E.R. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler. Thromb. Vasc. Biol. 2001, 21:2080-2085.
6. Hamelet J., Noll C., Ripoll C., Paul J.L., Janel N., Delabar J.M. Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. Biochem. Biophys. Res. Commun. 2009, 378:673-677.
7. Noll C., Planque C., Ripoll C., Guedj F., Diez A., Ducros V., Belin N., Duchon A., Paul J.L., Badel A., Freminville B., Grattau Y., Bléhaut H., Herault Y., Janel N., Delabar J.M. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS One 2009, 4:e7540.
8. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
9. Guedj F., Pereira P.L., Najas S., Barallobre M.J., Chabert C., Souchet B., Sebrie C., Verney C., Herault Y., Arbones M., Delabar J.M. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol. Dis. 2012, 46:190-203.
10. C. Planque, J. Dairou, C. Noll, L.-N. Bui, C. Ripoll, F. Guedj, J.M. Delabar, N. Janel, Mice deficient in cystathionine beta synthase display increased Dyrk1A and SAHH activities in brain, J. Mol. Neurosci. (in press).
11. Finkelstein J.D. The metabolism of homocysteine: pathways and regulation. Eur. J. Pediatr. 1998, 157:S40-S44.
12. Stead L.M., Brosnan M.E., Brosnan J.T. Characterization of homocysteine metabolism in the rat liver. Biochem. J. 2000, 350:685-692.
13. Van Linthout S., Lusky M., Collen D., De Geest B. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther. 2002, 9:1520-1528.
14. Becker W., Joost H.G. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog. Nucleic Acid Res. Mol. Biol. 1999, 62:1-17.
15. Jacobs F., Snoeys J., Feng Y., Van Craeyveld E., Lievens J., Armentano D., Cheng S.H., De Geest B. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther. 2008, 15:594-603.
16. Watanabe M., Osada J., Aratani Y., Kluckman K., Reddick R., Malinow M.R., Maeda N. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1585-1589.
17. Van Linthout S., Foryst-Ludwig A., Spillmann F., Peng J., Feng Y., Meloni M., Van Craeyveld E., Kintscher U., Schultheiss H.P., De Geest B., Tschöpe C. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 2010, 210:438-444.
18. Jacobs F., Van Craeyveld E., Muthuramu I., Gordts S.C., Emmerechts J., Hoylaerts M., Herijgers P., De Geest B. Correction of endothelial dysfunction after selective homocysteine lowering gene therapy reduces arterial thrombogenicity but has no effect on atherogenesis. J. Mol. Med. 2011, 89:1051-1058.
19. Van Craeyveld E., Gordts S.C., Nefyodova E., Jacobs F., De Geest B. Regression and stabilization of advanced murine atherosclerosis lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J. Mol. Med. 2011, 89:555-567.
20. Van Craeyveld E., Jacobs F., Gordts S.C., De Geest B. Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther. 2012, 19:860-871.
21. Hamelet J., Ait-Yahya-Graison E., Matulewicz E., Noll C., Badel-Chagnon A., Camproux A.C., Demuth K., Paul J.L., Delabar J.M., Janel N. Homocysteine threshold value based on cystathionine beta synthase and paraoxonase 1 activities in mice. Eur. J. Clin. Investig. 2007, 37:933-938.
22. Omura T., Sadano H., Hasegawa T., Yoshida Y., Kominami S. Hemoprotein H-450 identified as a form of cytochrome P-450 having an endogenous ligand at the 6th coordination position of the heme. J. Biochem. 1984, 96:1491-1500.
23. Troncale S., Barbet A., Coulibaly L., Henry E., He B., Barillot E., Dubois T., Hupé P., de Koning L. NormaCurve: a supercurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One 2012, 7:e38686.
24. Villanueva J.A., Halsted C.H. Hepatic transmethylation reactions in micropigs with alcoholic liver disease. Hepatology 2004, 39:1303-1310.
25. Benson A.M., Hunkeler M.J., Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:5216-5220.
26. Miller J.W., Nadeau M.R., Smith J., Smith D., Selhub J. Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism. Biochem. J. 1994, 298:415-419.
27. Gellekink H., van Oppenraaij-Emmerzaal D., van Rooij A., Struys E.A., den Heijer M., Blom H.J. Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. Clin. Chem. 2005, 51:1487-1492.
28. Bisp M.R., Bor M.V., Heinsvig E.M., Kall M.A., Nexo E. Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal. Biochem. 2002, 305:82-89.
29. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
30. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl. Res. 2009, 153:77-85.
31. Robert K., Chasse J.F., Santiard-Baron D., Vayssettes C., Chabli A., Aupetit J., Maeda N., Kamoun P., London J., Janel N. Altered gene expression in liver from a murine model of hyperhomocysteinemia. J. Biol. Chem. 2003, 278:31504-31511.
32. Noll C., Hamelet J., Matulewicz E., Paul J.L., Delabar J.M., Janel N. Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J. Nutr. Biochem. 2009, 20:586-596.22.
33. Lan T.H., Xu Z.W., Wang Z., Wu Y.L., Wu W.K., Tan H.M. Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition. Biochem. Pharmacol. 2011, 82:148-155.
34. McAlpine C.S., Bowes A.J., Khan M.I., Shi Y., Werstuck G.H. Endoplasmic reticulum stress and glyxogen synthase kinase-3b activation in apolipoprotein E-deficient mouse models of accelerated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:82-91.
35. Abekhoukh S., Planque C., Ripoll C., Urbaniak P., Paul J.L., Delabar J.M., Janel N. Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in brain of hyperhomocysteinemic mice. Mol. Neurobiol. 2013, 47:105-116.
36. Collaboration H.S. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
37. Ebbing M., Bonaa K.H., Nygard O., Arnesen E., Ueland P.M., Nordrehaug J.E., Rasmussen K., Njolstad I., Refsum H., Nilsen D.W., Tverdal A., Meyer K., Vollset S.E. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009, 302:2119-2126.
38. Noll C., Tlili A., Ripoll C., Mallet L., Paul J.L., Delabar J.M., Janel N. Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism. Mol. Genet. Metab. 2012, 105:484-488.
39. Hershfield M.S., Aiyar V.N., Premakumar R., Small W.C. S-Adenosylhomocysteine hydrolase from human placenta. Affinity purification and characterization. Biochem. J. 1985, 230:43-52.
40. Hoffman D.R., Cornatzer W.E., Duerre J.A. Relationship between tissue levels of S-adenosylmethionine, S-adenylhomocysteine, and transmethylation reactions. Can. J. Biochem. 1979, 57:56-65.
41. Kerins D.M., Koury M.J., Capdevila A., Rana S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am. J. Clin. Nutr. 2001, 74:723-729.
42. Mikael L.G., Genest J., Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 2006, 98:564-571.
43. Hernandez-Trujillo Y., Rodriguez-Esparragon F., Macias-Reyes A., Caballero-Hidalgo A., Rodriguez-Perez J.C. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. Cardiovasc. Diabetol. 2008, 7:3.
44. Gouedard C., Barouki R., Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 2004, 24:5209-5222.
45. Pasqualini L., Cortese C., Marchesi S., Siepi D., Pirro M., Vaudo G., Liberatoscioli L., Gnasso A., Schillaci G., Mannarino E. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005, 183:349-354.
46. Norata G.D., Catapano A.L. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc. Health Risk Manag. 2005, 1:119-129.
47. Liu W.H., Zhao Y.S., Gao S.Y., Li S.D., Cao J., Zhang K.Q., Zou C.G. Hepatocyte proliferation during liver regeneration is impaired in mice with methionine diet-induced hyperhomocysteinemia. Am. J. Pathol. 2010, 177:2357-2365.
48. Liu W.J., Ma L.Q., Liu W.H., Zhou W., Zhang K.Q., Zou C.G. Inhibition of hepatic glycogen synthesis by hyperhomocysteinemia mediated by TRB3. Am. J. Pathol. 2011, 178:1489-1499.
49. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., Lensch M.W., Park I.H., Yoon S.S., Minami T., Korenberg J.R., Folkman J., Daley G.Q., Aird W.C., Galdzicki Z., Ryeom S. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
50. Yu S., Khor T.O., Cheung K.L., Li W., Wu T.Y., Huang Y., Foster B.A., Kan Y.W., Kong A.N. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010, 5:e8579.
51. Malinge S., Bliss-Moreau M., Kirsammer G., Diebold L., Chlon T., Gurbuxani S., Crispino J.D. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J. Clin. Invest. 2012, 122:948-962.
52. Konukoglu D., Serin O., Turhan M.S. Plasma total homocysteine concentrations in obese and non-obese female patients with type 2 diabetes mellitus; its relations with plasma oxidative stress and nitric oxide levels. Clin. Hemorheol. Microcirc. 2005, 33:41-46.
53. Medici V., Peerson J.M., Stabler S.P., French S.W., Gregory J.F., Virata M.C., Albanese A., Bowlus C.L., Devaraj S., Panacek E.A., Rahm N., Richards J.R., Rossaro L., Halsted C.H. Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. J. Hepatol. 2010, 53:551-557.
54. Yun K.U., Ryu C.S., Oh J.M., Kim C.H., Lee K.S., Lee C.H., Lee H.S., Kim B.H., Kim S.K. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet. Eur. J. Nutr. 2013, 52:127-134.